ibrutinib + bortezomib + dexamethasone

Ibrutinib + bortezomib + dexamethasone is a combination regimen of three pharmaceutical agents: - **Ibrutinib**: a first-in-class, orally administered, covalent small molecule inhibitor of Bruton's tyrosine kinase (BTK), a key mediator of B-cell receptor signaling involved in proliferation and survival of malignant B-cells. - **Bortezomib**: a reversible small molecule inhibitor of the 26S proteasome, interfering with the degradation of ubiquitinated proteins involved in cell cycle and apoptosis, particularly relevant in plasma cell malignancies. - **Dexamethasone**: a synthetic corticosteroid (glucocorticoid), acting as a broad immunosuppressant and anti-inflammatory agent, commonly used to augment response to antineoplastic regimens. This combination has been investigated in phase 2 studies for the treatment of relapsed or relapsed/refractory multiple myeloma, aiming to harness synergy between BTK inhibition and proteasome inhibition, in the context of glucocorticoid-driven enhancement of cell death in malignant plasma cells. The regimen showed clinical activity but was not advanced to further development, partly due to an inability to meet target endpoints for progression-free survival and increased risk of serious infection in heavily pretreated patients[1][7].

Other names

Ibrutinib + Bortezomib + DexamethasoneIBD regimen